Brokerages Set Vor Biopharma Inc. (NASDAQ:VOR) PT at $76.50

Vor Biopharma Inc. (NASDAQ:VOR) has earned a consensus rating of “Hold” from the eleven analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $76.50.

A number of research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Zacks Research lowered Vor Biopharma from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Stifel Nicolaus raised Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Wednesday, September 24th. HC Wainwright raised their target price on Vor Biopharma to $52.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $18.70 on Friday. Vor Biopharma has a 12 month low of $2.62 and a 12 month high of $65.80. The company’s 50 day moving average is $31.74. The firm has a market capitalization of $128.10 million, a P/E ratio of -0.07 and a beta of 2.02.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Insiders Place Their Bets

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 260,859 shares of the firm’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $29.39, for a total value of $7,666,646.01. Following the sale, the director directly owned 15,104 shares in the company, valued at $443,906.56. This trade represents a 94.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12. Following the transaction, the insider owned 32,781,209 shares in the company, valued at approximately $50,483,061.86. The trade was a 1.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 2,431,718 shares of company stock worth $62,090,254 in the last ninety days. 0.45% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds have recently made changes to their positions in the stock. Ariose Capital Management Ltd acquired a new stake in Vor Biopharma during the third quarter worth about $5,368,000. XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the 2nd quarter worth approximately $66,000. Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Vor Biopharma during the 1st quarter worth approximately $140,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma during the first quarter valued at approximately $100,000. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.